Mustang Bio Reports Fourth Quarter and Full-Year 2017 Financial Results and Recent Corporate Highlights
pharmaceutical investing Dermira’s Two Phase 3 Trials Evaluating Olumacostat Glasaretil in Patients with Acne Vulgaris Did Not Meet Co-Primary Endpoints
Dermira Initiates Phase 2b Dose-Ranging Study Evaluating Lebrikizumab in Patients with Moderate-to-Severe Atopic Dermatitis
MacroGenics Announces Continuation of SOPHIA Study of Margetuximab Based on Completion of Interim Futility Analysis
Equity Metals Reports First Assays from No. 3 North 2025 Expansion Drilling, Including 540 g/t AgEq over 3.5m, Silver Queen Property, BC
